Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 29, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding share ownership changes within an employee retirement plan and does not contain financial performance data.
Material Changes
The only material change reported is a reduction in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 16,684,320 ADRs
- New Holding: 16,678,463 ADRs
- Change Date: January 26, 2007
- Average Price: $54.85
This change resulted from a movement in the fund. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in these shares as beneficiaries of the discretionary fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the impact of the ADR reduction on the total share count of the US Retirement Savings Plan.
- Confirm the specific nature of the "movement in the fund" that triggered the transaction.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance context.
- Note that this filing does not reflect operational or financial performance for the period.